RxDoctor Payments Data

Linda Chen, MD

Neurology · Santa Barbara, CANPI 1629105069

Payments from drug & device makers

$13,640in general payments, 2019–2025

Across 645 payments — averaging $21.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Novartis$943
  • Pfizer$722
  • UCB, Inc.$694
  • Biogen$634
  • SK Life Science, Inc.$483
  • plus $7K from 51 others

What the payments were for

  • Speaking & faculty fees$691%
  • Travel & lodging$3032%
  • Food & beverage$13,20397%
  • Education$660%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)187$3,173
Novartis48$943
Pfizer43$722
UCB, Inc.27$694
Biogen32$634
SK Life Science, Inc.10$483
Sanofi20$465
Medtronic5$451
TG Therapeutics, Inc.11$409
Jazz Pharmaceuticals Inc.10$382
Teva Pharmaceuticals USA, Inc.20$377
Genentech USA, Inc.17$349
Amgen13$325
Neurelis, Inc.7$289
Eisai Inc.9$287
Lilly USA, LLC12$263
Lundbeck LLC10$261
Amneal Pharmaceuticals LLC12$236
EMD Serono, Inc.19$220
CSL Behring5$198
Greenwich Biosciences, Inc.13$175
Neuropace, Inc.2$168
AstraZeneca8$162
Acadia Pharmaceuticals Inc7$139
Supernus Pharmaceuticals, Inc.18$138
Inspire Medical Systems, Inc.5$115
Tanabe Pharma America, Inc.5$113
Argenx US, Inc.4$111
Livanova USA, Inc.5$96
Vanda Pharmaceuticals Inc.3$96
Biohaven Pharmaceutical Holding Company Ltd.4$92
Sunovion Pharmaceuticals Inc.7$90
MDD US Operations, LLC5$85
Acorda Therapeutics, Inc5$69
Kedrion Biopharma, Inc.2$68
Impel Pharmaceuticals Inc.3$66
Sumitomo Pharma America, Inc.3$64
Mallinckrodt Hospital Products Inc.2$61
Grifols USA, LLC3$60
Portola Pharmaceuticals, LLC2$55
Merz Pharmaceuticals, LLC2$46
Adamas Pharmaceuticals, Inc.2$46
Otsuka America Pharmaceutical, Inc.2$42
Alnylam Pharmaceuticals Inc.2$39
Takeda Pharmaceuticals U.S.A., Inc.2$34
Neurocrine Biosciences, Inc.1$25
Bristol Myers Squibb1$25
Promius Pharma LLC1$24
Banner Life Sciences, LLC1$24
Octapharma USA, Inc.1$23
Catalyst Pharmaceuticals, Inc.1$23
Johnson & Johnson1$20
Kyowa Kirin, Inc.1$19
Averitas Pharma Inc.1$18
Assertio Therapeutics, Inc.1$17
Upsher-smith Laboratories LLC1$15
Scilex Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,640 in reported general payments places this provider in the 75th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$94,998
Medicare patients
264
Services billed
7,376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EpidiolexCannabidiol (Cbd)25$135,647
Rebif RebidoseInterferon Beta-1a/Albumin13$134,518
Emgality PenGalcanezumab-Gnlm92$76,112
UbrelvyUbrogepant49$51,582
Nurtec OdtRimegepant Sulfate26$35,492
Aimovig AutoinjectorErenumab-Aooe43$34,027
TrileptalOxcarbazepine19$29,737
DepakoteDivalproex Sodium22$22,317
Keppra XrLevetiracetam12$14,696
QuliptaAtogepant12$13,268
Levetiracetam279$13,194
Lacosamide36$12,038
Dalfampridine ErDalfampridine51$11,675
SpritamLevetiracetam13$9,103
TegretolCarbamazepine15$6,489

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$3,173$64,85061 claims
PfizerNurtec Odt, Dilantin$722$38,35537 claims
Upsher-smith Laboratories LLCTopiramate$15$1,26378 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →